US Edition
News from hcplive.com
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top hcplive.com News
Novo Nordisk · DenmarkNovo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
76% Center coverage: 33 sources
FDA · United StatesThe U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Monday for Unicycive Therapeutics, Inc.’s (NASDAQ:UNCY) New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Hyperphosphatemia is a condition characterized by elevated phosphate levels in the blood, most commonly resulting from impaired kidney function, and can lead to comp…See the Story
FDA Raises Manufacturing Concerns, Delays Unicycive's Kidney Disease Drug Approval - Unicycive Therapeutics (NASDAQ:UNCY)
67% Center coverage: 3 sources
